Aloe Vera and IBS
What 5 graded rows on aloe vera agree on for IBS, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Aloe Vera page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Aloe Vera page, with its PubMed record.
Your question
Aloe Vera and IBS
5 rows · 736 peopleMostly no difference: 4 of 5 rows, and most of the people. 1 found an improvement.
- CGrade C× 3
- DGrade D× 2
- Rows
- 5
- Trials
- 9
- People
- 736
- Pooled reviews may count some twice
Where they differ
From the rowsThe best-graded row, grade C, is a meta-analysis of 299 people (2026) and found no difference.
By our six checks (size, design, length, who was studied, year and grade), the two sides do not differ cleanly. The dose and how each outcome was measured are in the rows below.
The rows
1 improved · 4 no difference- CGrade CIBS global symptom response · No difference
Meta-analysis, 3 studies · n 299 · 2026 · Adults with irritable bowel syndrome (3 RCTs: Davis 2006, Størsrud 2015, Ahluwalia 2020)
50 mL juice four times daily, two tablets daily, or 250 mg twice daily (per included trial) · About 4 weeks per trial
62 of 155 people on aloe improved; the pooled risk ratio was 1.25 (95% CI 0.76–2.06), not significant, with moderate heterogeneity (I² 56%). Adverse events were few on aloe (4 in 153) and no more common than on control.
- CGrade CIBS symptom severity vs an inulin control · No difference
RCT · n 160 · 2020 · Adults with IBS, all subtypes (Sweden)
250 mg twice daily · 4 weeks
Symptoms fell in both groups with no difference between aloe and inulin (P=0.62); responders 39% vs 45%.
- DGrade DIBS responders and symptom severity (AVH200) · No difference
Pilot RCT · n 68 · 2015 · Adults with IBS by Rome III criteria (Sweden)
One tablet twice daily · 4 weeks
The primary endpoint was not met: 55% vs 31% responders (P=0.09) and no significant between-group difference in symptom severity (P=0.10).
- DGrade DIBS response in refractory patients · No difference
RCT · n 58 · 2006 · Secondary-care patients with refractory IBS (UK)
50 mL four times daily · 1 month (follow-up to 3 months)
Response at 1 month was 35% with aloe vs 22% with placebo (P=0.763); diarrhoea-predominant patients showed a non-significant trend.
- CGrade CIBS symptom scores and response rate · Improved
Meta-analysis, 3 studies · n 151 · 2018 · Adults with irritable bowel syndrome (3 RCTs)
50 mL four times daily, 60 mL twice daily, or one tablet twice daily (per included trial) · 4 weeks to 5 months
Symptom scores improved more than placebo (SMD 0.41) and response rates were higher (RR 1.69); no aloe-related adverse events were reported. The benefit was seen at 1 month but not beyond 3 months.